Japanese Journal of Cancer and Chemotherapy最新文献_第2页

[A Case of Aggressive Angiomyxoma Completely Resected with Organ Preservation by Preoperative Hormone Therapy]. 侵袭性血管粘液瘤经术前激素治疗完全切除并保留器官1例。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-09-01

Masato Kambe, Sumito Sato, Makoto Tatsumi, Tatsuya Kinjo, Takashi Hamano, Yasuyuki Kobayashi

{"title":"[A Case of Aggressive Angiomyxoma Completely Resected with Organ Preservation by Preoperative Hormone Therapy].","authors":"Masato Kambe, Sumito Sato, Makoto Tatsumi, Tatsuya Kinjo, Takashi Hamano, Yasuyuki Kobayashi","doi":"","DOIUrl":"","url":null,"abstract":"A 34‒year‒old woman presented with a pelvic tumor in the Douglas pouch during her first pregnancy, initially suspected to be a desmoid tumor and managed subsequently. Biopsy during cesarean section in her second pregnancy confirmed aggressive angiomyxoma (AAM). Postpartum tumor growth prompted a 16‒month course of gonadotropin‒releasing hormone agonist therapy (leuprorelin acetate, 1.88 mg every 4 weeks), which reduced tumor size from 20×13 cm to 10×7.5 cm after 12 doses. However, adverse effects, such as fatigue and nausea occurred, and further tumor shrinkage was minimal, necessitating surgical intervention. A left posterior sacral approach allowed complete tumor resection while preserving the rectum, reproductive organs, and autonomic nerves. AAM is a rare tumor of the pelvis or external genitalia in young women. Although surgical excision remains the primary treatment, no standardized approach exists. This case demonstrates the role of preoperative hormone therapy in significantly reducing tumor size, thereby facilitating complete excision with organ preservation, and underscore its potential role in AAM management.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 9","pages":"685-687"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The Significance of TLS in Patients with Gastric Cancer]. 【TLS在胃癌患者中的意义】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-09-01

Masaki Nishiyama, Yuichiro Miki, Hiroaki Tanaka, Kiyoshi Maeda

引用次数: 0

[Breast Cancer‒Associated Allergy Caused by Fosnetupitant-A Report of Four Cases]. 福斯妥吡坦致乳腺癌相关过敏4例报告

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-09-01

Masaru Takemae, Yumiko Ishikawa, Tomoka Toyota, Jiro Ando

{"title":"[Breast Cancer‒Associated Allergy Caused by Fosnetupitant-A Report of Four Cases].","authors":"Masaru Takemae, Yumiko Ishikawa, Tomoka Toyota, Jiro Ando","doi":"","DOIUrl":"","url":null,"abstract":"We describe the cases of 4 patients with breast cancer who developed an allergy to fosnetupitant (Pro‒NETU). Case 1: A 67‒year‒old woman with breast cancer and bone metastasis received premedication that included Pro‒NETU. Minutes after administration, she complained of flushing, tachycardia, and dyspnea. Administration was discontinued. Minutes after discontinuation, the patient's symptoms were alleviated. She experienced no further complaints of such symptoms, and her premedication subsequently excluded Pro‒NETU. Case 2: A 50‒year‒old woman with early stage breast cancer received premedication that included Pro‒NETU. Minutes after administration, she complained of flushing, dyspnea, and drowsiness. Administration was discontinued. Minutes after discontinuation, her symptoms ameliorated. Case 3: A 41‒year‒old woman with early stage breast cancer received premedication that included Pro‒NETU. Minutes after administration, she complained of flushing, tachycardia, and dyspnea. Administration was thus discontinued, and she received an H2‒blocker and corticosteroid. Minutes after discontinuation, her symptoms were alleviated. Case 4: A 50‒year‒old woman with early stage breast cancer received premedication that included Pro‒NETU. Minutes after administration, she complained of flushing and tachycardia. Administration was discontinued. Minutes after discontinuation, her symptoms ameliorated. Fosaprepitant did not cause these allergies. The patients in cases 2, 3, and 4 had known allergies to docetaxel, and the cause of allergy in case 4 was unknown. Polysorbate 80, contained in docetaxel, fosaprepitant, and Pro‒NETU, was suspected to be the cause of allergy in cases 1, 2, and 3.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 9","pages":"677-679"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Tertiary Lymphoid Structures as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Esophageal Cancer]. [三级淋巴结构作为食管癌免疫检查点抑制剂治疗的预测性生物标志物]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-09-01

Yoshinori Hayashi, Tomoki Makino, Yuichiro Doki

{"title":"[Tertiary Lymphoid Structures as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Esophageal Cancer].","authors":"Yoshinori Hayashi, Tomoki Makino, Yuichiro Doki","doi":"","DOIUrl":"","url":null,"abstract":"While immune checkpoint inhibitors(ICIs)have dramatically improved treatment outcomes for esophageal cancer in recent years, substantial interpatient variability in therapeutic response remains a major clinical challenge. The development of reliable predictive biomarkers to identify patients likely to benefit from ICI therapy is thus an urgent priority. Conventional biomarkers such as programmed death‒ligand 1(PD‒L1)expression, tumor mutational burden(TMB), and microsatellite instability(MSI)have shown limited predictive utility and clinical applicability in esophageal cancer. These markers primarily reflect tumor‒intrinsic properties and may fail to capture the complex interplay between the tumor and its immune microenvironment. Tertiary lymphoid structures(TLS), ectopic lymphoid aggregates formed within the tumor microenvironment, have recently emerged as promising immune‒related biomarkers. TLS represent organized immune cell niches capable of facilitating local antigen presentation and adaptive immune activation. In this review, we provide an overview of key phase Ⅲ clinical trials of ICIs in esophageal cancer, with a particular focus on the biomarkers used in each study. We then summarize the structural and functional characteristics of TLS and highlight accumulating evidence supporting their value as predictive indicators of ICI efficacy. We further compare TLS with existing biomarkers, discussing the advantages and limitations of TLS assessment in clinical settings. Finally, we explore the future potential of TLS as both a biomarker and a therapeutic target, including the development of strategies aimed at promoting TLS formation to enhance anti‒tumor immunity. TLS offer a novel, immune microenvironment‒reflective dimension to patient stratification, and their integration into biomarker frameworks may refine personalized immunotherapy approaches for esophageal cancer.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 9","pages":"618-623"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Large Primary Hepatic Neuroendocrine Tumor with Right Trisectionectomy-A Case Report]. 【原发性肝脏大神经内分泌肿瘤伴右侧三节切除术1例】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-09-01

Ryohei Aoyama, Takumi Miyamoto, Kentaro Yasuchika, Masaya Tsubakiyama, Hyoma Terawaki, Yusuke Sakura, Hideaki Tsujii

{"title":"[Large Primary Hepatic Neuroendocrine Tumor with Right Trisectionectomy-A Case Report].","authors":"Ryohei Aoyama, Takumi Miyamoto, Kentaro Yasuchika, Masaya Tsubakiyama, Hyoma Terawaki, Yusuke Sakura, Hideaki Tsujii","doi":"","DOIUrl":"","url":null,"abstract":"A large mass in the liver was incidentally observed on abdominal ultrasonography of a 75‒year‒old female during health surveillance. Computed tomography (CT) and magnetic resonance imaging revealed a tumor (φ>12 cm) in the medial segment of the liver. A liver biopsy was performed, and the tumor was histopathologically diagnosed as a neuroendocrine tumor (NET) G1. 18F‒fluorodeoxyglucose positron emission tomography‒CT (PET‒CT) and somatostatin receptor scintigraphy (SRS) revealed concomitant uptake in the hepatic tumor and no abnormal uptake in other organs; thus, the tumor was diagnosed as a primary hepatic NET (PHNET). Radical resection required right trisectionectomy of the liver, with little future remnant liver volume. The radical resection was performed 3 weeks post portal embolization. There were no surgical complications or obvious recurrence for 1 year post‒surgery. PHNETs are extremely rare and are difficult to diagnose using routine imaging modalities. PET‒CT and SRS are useful to exclude the presence of extrahepatic lesions and histopathological examination is required to diagnose PHNETs. Surgical resection is the first‒line treatment for PHNETs and even if the PHNET is large, a favorable prognosis can be achieved with radical resection.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 9","pages":"681-684"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster]. 新发传染病灾害下医学肿瘤学的挑战与展望

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-08-01

Sachi Morita, Noritoshi Kobayashi, Junji Tsurutani, Haruko Daga, Emiko Ohki, Takami Kashiwada, Kentaro Kawakami, Yoshiko Kitagawa, Masaki Maruta, Yasuhiro Fujiwara, Hironobu Minami

引用次数: 0

[A Case of Long-Term Complete Remission with Solitary Metastasis Following Surgery and Chemotherapy for Ascending Colon Cancer]. 【升结肠癌手术化疗后长期完全缓解伴单发转移1例】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-08-01

Kaiki Murai, Teruo Kaiga, Gotaro Katsuno, Takao Mamiya, Ikuko Matsumoto, Tomoharu Kurokawa, Yasuhiko Nakata

引用次数: 0

[Appendiceal Tumors, Up to Date]. [最新阑尾肿瘤]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-08-01

Yukiko Morinaga, Mitsuo Kishimoto

{"title":"[Appendiceal Tumors, Up to Date].","authors":"Yukiko Morinaga, Mitsuo Kishimoto","doi":"","DOIUrl":"","url":null,"abstract":"Appendiceal tumors are relatively rare and their classification remains controversial. In particular, for tumors specific to the appendix, such as appendiceal mucinous neoplasm and goblet cell adenocarcinoma, understanding the disease has become difficult due to transition of terminology and complex grading systems. There has been little large-scale data on appendiceal tumors in Japan, but a full picture is gradually emerging on account of project research by the Japanese Society for Cancer of Colon and Rectum. Now, we explain the overview of appendiceal mucinous neoplasm and goblet cell adenocarcinoma, as well as their histological grading and staging system, including the latest findings, and describe their impact on patient prognosis and treatment. Both of these tumors frequently cause clinical problems due to peritoneal dissemination. In Europe and the United States, the combination of cytoreductive surgery(CRS)and hyperthermic intraperitoneal chemotherapy(HIPEC)is recommended, but in Japan, HIPEC is not widely used, so there is not enough data available. There are still many unknowns about appendiceal tumors, so it is important to clarify the concept of the disease and accumulate accurate data. In addition, the histological classification of appendiceal tumors in this article conforms to Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma, 9th edition and the WHO Classification, 5th edition, although new editions of both are scheduled to be published soon. The outlook for the 10th edition of the Japanese Classification is briefly mentioned in the text, but please note that the classification introduced here may be subject to change.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 8","pages":"549-554"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144972256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Unresectable Advanced Gastric Cancer with Pathological Complete Response to SOX plus Nivolumab Therapy]. [1例不可切除的晚期胃癌对SOX联合纳武单抗治疗病理完全缓解]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-08-01

Keisuke Yasuda, Naoki Urakawa, Ryuichiro Sawada, Taro Ikeda, Yasufumi Koterazawa, Takeaki Aoki, Hitoshi Harada, Yasunori Otowa, Hironobu Goto, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji

{"title":"[A Case of Unresectable Advanced Gastric Cancer with Pathological Complete Response to SOX plus Nivolumab Therapy].","authors":"Keisuke Yasuda, Naoki Urakawa, Ryuichiro Sawada, Taro Ikeda, Yasufumi Koterazawa, Takeaki Aoki, Hitoshi Harada, Yasunori Otowa, Hironobu Goto, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji","doi":"","DOIUrl":"","url":null,"abstract":"The patient was a 79-year-old male diagnosed with gastric cancer with lung metastasis(cT3N2M1[PUL], cStage ⅣB)and sigmoid colon cancer(cT3N0M0, cStage Ⅱa). He underwent systemic chemotherapy with the SOX plus nivolumab regimen for unresectable advanced gastric cancer. Six months after the initiation of chemotherapy(9 courses), the primary tumor and lymph node metastases in the lesser curvature and suprapancreatic margin had shrunk, and the lung metastases had disappeared. However, chemotherapy was discontinued because of the development of immune-related interstitial pneumonia, and steroid therapy was initiated. Nine months after the initiation of chemotherapy, the tumor shrinkage rate remained constant and interstitial pneumonia improved; however, the patient was referred to our hospital for surgical treatment for gastric stenosis. A laparoscopic distal gastrectomy was performed for gastric cancer. Histopathological findings revealed no residual cancer cells in the primary tumor or lymph nodes, and the histological response was Grade 3. The patient remained recurrence-free for 10 months after the surgery. SOX plus nivolumab therapy for unresectable advanced gastric cancer is expected to have a high tumor-shrinkage effect, and combining it with conversion surgery may lead to an improved long-term prognosis.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 8","pages":"601-603"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144972262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Outcome of Cytoreductive Surgery(CRS)+Hyperthermic Intraperitoneal Chemotherapy(HIPEC)for Appendiceal Pseudomyxoma Peritonei]. [细胞减少手术(CRS)+腹腔高温化疗（HIPEC）治疗阑尾腹膜假性黏液瘤的疗效]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-08-01

Mitsuhiro Morikawa, Takanori Goi

引用次数: 0